Soleno Therapeutics to Participate in Upcoming Conferences

Group 1 - Soleno Therapeutics, Inc. is participating in several investor conferences in February and March 2026, including the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference [1] - The company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, was approved by the FDA on March 26, 2025, for the treatment of hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [2]